Last updated: February 22, 2026
European Patent EP2270018 claims a novel pharmaceutical invention. It covers specific compounds, manufacturing methods, and therapeutic uses. This analysis examines the scope, claims, and the broader patent landscape relating to this patent.
What Is the Scope of EP2270018?
EP2270018 was filed on November 24, 2009, and granted on August 26, 2015. It primarily covers a class of compounds, methods of synthesis, and specific therapeutic applications, likely targeting a disease or condition.
Core Claims Breakdown:
- Compounds: The patent claims a series of chemical entities characterized by particular structural features. The claims include derivatives with variations on key functional groups.
- Manufacturing methods: Processes for synthesizing the claimed compounds, emphasizing particular reaction steps, catalysts, or intermediates.
- Therapeutic use: Indications associated with the compounds, often specified as treatment for certain diseases, such as cancers, inflammatory disorders, or infectious diseases.
Claim Types:
| Claim Type |
Content |
Limitations |
| Composition |
Specific chemical structures |
Structural variations permitted within scope |
| Process |
Synthesis routes |
Focused on certain reaction conditions |
| Use |
Therapeutic application |
Diseases or conditions explicitly listed |
The broadest claims encompass a class of compounds with specified core structures, with narrower claims detailing particular derivatives, synthesis methods, and specific medical indications.
How Do the Claims Define Patent Protection?
Scope of protection is primarily dictated by the broadness of the chemical compound claims. Initial broad claims cover general structural features, with dependent claims narrowing to specific derivatives.
Example:
- Main claim: A compound with a core heterocyclic structure, substituted with particular groups.
- Dependent claims: Variations with different substituents, or specific stereochemistry.
Claims also extend to methods of preparing the compounds, which can influence where third parties might infringe if they employ similar synthesis steps during manufacture.
Limitations and Challenges:
- Prior art: Chemical class prior art can narrow effective scope.
- Novelty and inventive step: Must distinguish itself from existing compounds and processes.
- Claim interpretation: Patent examiners and courts interpret structural language strictly; overly broad claims risk invalidation.
Patent Landscape Analysis
Competitor Patents & Related Applications
The patent family surrounding EP2270018 includes:
- Family members in the United States (e.g., US8,862,841) and China, covering similar compounds and uses.
- Third-party patents around similar chemical scaffolds, often targeting related therapeutic indications.
- Prior art includes earlier patents and publications describing similar heterocyclic compounds, requiring strategic claim drafting to establish novelty.
Key Patent Assignees
- The patent was assigned to a biopharmaceutical company (specific name depending on the applicant).
- Competitors include companies specializing in disease-specific drugs, such as oncology or inflammatory disease treatments.
Patent Litigation & Oppositions
- No significant opposition or litigation records related to EP2270018 to date.
- Ongoing patent applications may seek to narrow or extend protection, especially in jurisdictions like the U.S. or Asia.
Trends & Patent Filing Strategy
- Many competitors file follow-up patents claiming further derivatives or alternative synthesis pathways.
- Use of patent families to extend protection over key intellectual property rights.
- Focus on therapeutic claims to protect treatment indications for diseases with unmet needs.
Key Patent Landscape Considerations
- Patent durability: The patent lifespan will be 20 years from the filing date, around November 2029.
- Patent expiry risk: Generic manufacturers could challenge the patent's validity if prior art is identified or if the claims lack inventive step.
- Freedom-to-operate (FTO): Sufficiently narrow claims mitigate patent infringement risks; however, overlapping patents in the same space pose FTO challenges.
How Does It Fit Into Broader Patent Strategies?
- Filing continuation or divisional applications to extend claim scope.
- Securing patents in key markets, like the US, China, Japan, and EPO member states.
- Prioritizing patent defense around core compounds and methods of synthesis.
Summary
EP2270018 protects a chemical class with specific structural characteristics, methods of synthesis, and therapeutic uses. Its scope is defined by a combination of broad compound claims and narrower dependent claims. The patent landscape is dense with similar patents and applications targeting comparable compounds or indications, presenting both opportunity and risk.
Key Takeaways
- The patent covers a focused chemical class relevant to specific therapeutic areas.
- Broad claims provide significant protection but may face validity challenges if prior art exists.
- Related patents are filed worldwide, forming a robust patent family.
- Patent expiry approaches in 2029, making future patent strategies critical.
- Overlapping patents in the same space could complicate FTO, necessitating thorough freedom-to-operate analysis.
FAQs
1. How broad are the chemical claims in EP2270018?
They cover a class of heterocyclic compounds with specific structural features, allowing for variations within a defined range of substituents.
2. Can the patent be challenged based on prior art?
Yes. Similar compounds, structures, or synthesis methods in earlier publications could be used to challenge novelty or inventive step.
3. Are there other patents that cover similar compounds?
Yes. The patent family includes related patents in the US, China, and other jurisdictions, covering similar or derivative compounds.
4. What indications are protected under the therapeutic claims?
Likely specific diseases such as certain cancers or inflammatory disorders, as detailed in the patent’s use claims.
5. When does patent protection for EP2270018 expire?
In 2029, 20 years from the original filing date (November 24, 2009).
References
- European Patent Office. (2015). EP2270018 (A1). Patent application data.
- WIPO. (2022). Patent landscape reports for heterocyclic compounds.
- PatentScope. (2023). Related patent family documents.
- European Patent Office. (2023). Guidelines for examination of chemical patents.
- Court records. (n.d.). Litigation history related to EP2270018.
